Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Quarterly Report · 10-Q

Endo LP

Quarterly Report

Filed Aug 29, 2024Accepted Aug 29, 2024, 4:48 AM EDTCIK 2008861Accession 0002008861-24-000009
Share

Company context

Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.

Recent company filings

  1. 15-15D filingAug 5, 2025
  2. EFFECT filingAug 4, 2025
  3. S-8 POS filingAug 1, 2025
  4. POS AM filingAug 1, 2025
  5. Completion of Acquisition or Disposition of Assets · Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Material Modification to Rights of Security Holders · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAug 1, 2025

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗